Leucapheresis
Leucapheresis 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为HIV-1-infection、HIV Seropositivity。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
24 项
全球在招研究
0 项
已进入 III/IV 期
18 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- University Hospital, Ghent
- University of Washington
- N.N. Petrov National Medical Research Center of Oncology
- Hadassah Medical Organization
- Fred Hutchinson Cancer Center
- Erasmus Medical Center
- Johns Hopkins All Children's Hospital
- Miltenyi Biomedicine GmbH
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
比利时、美国、Russia、Israel、荷兰、奥地利、Croatia、Czechia、芬兰、法国、德国、Hungary
正在招募患者的 Leucapheresis 研究
Immuno-virological Evaluation of Persons Living With HIV (PLWH)
不适用招募中比利时NCT05973825Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T
II 期招募中美国NCT06784726High-dose Chemotherapy as Second-line Drug Therapy for Relapsed Germ Cell Tumors
II 期招募中RussiaNCT06418789Study of Naive HBI0101 CAR-T Therapy in Relapsed/Refractory Multiple Myeloma
I 期招募中IsraelNCT07333430Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer
I 期 / II 期招募中美国NCT06236139dENdritic Cell Therapy Combined With SURgEry in Mesothelioma
I 期招募中荷兰NCT05304208TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children
II 期招募中美国NCT04414046Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients
II 期招募中奥地利比利时CroatiaCzechiaNCT04844866Evaluate the Safety and Therapeutic Effects of a Single Intravenous Infusion (IV) of Autologous CD34+ Cells Enriched With Allogenic Placenta-derived Mitochondria in Patients With a Diagnosis of Pearson Syndrome (PS)
II 期招募中IsraelNCT06017869MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer
I 期招募中美国NCT06483048Efficacy and Safety of Anitocabtagene Autoleucel in Participants With Newly Diagnosed Multiple Myeloma (GEM-AnitoFIRST)
II 期招募中西班牙NCT07045909CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
II 期招募中美国NCT06059391Safety and Efficacy of Metabolically Armed BCMA CAR-T Cells (Meta10-BCMA) in the Treatment of r/r Plasma Cell Neoplasms Clinical Research
早期 I 期招募中中国NCT07085559CD7 CAR-T Cell Sequential Allo-HSCT for Non-malignant Blood and Immune System Diseases
早期 I 期招募中中国NCT06787560Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells
I 期招募中美国NCT06186401A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed/ Refractory Multiple Myeloma
早期 I 期招募中中国NCT06732232Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer
I 期 / II 期招募中美国NCT03942328Stem Cell Mobilization and Apheresis for Life-threatening Blood Disorders
I 期招募中美国NCT07585136The Use of Leukapheresis to Support HIV Pathogenesis Studies
不适用招募中美国NCT01161199Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy
II 期招募中美国NCT06930352CARPALL: Immunotherapy With CD19+CD22 CAR T-cells for CD19+ and CD22+ Acute Lymphoblastic Leukaemia
I 期招募中英国NCT02443831Locoregional Administration of Genetically Engineered Cells (EGFR/IL13Rα2 Pool-CAR T Cells) for the Treatment of Recurrent or Progressive High-Grade Gliomas
I 期招募中美国NCT07544992A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
I 期招募中美国NCT07020533COLLECT BLOOD/RESEARCH USE
不适用招募中美国NCT00001846
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。